LOL. Unfortunately you are seriously overestimating my molecular biology skills.
I've looked at some of their stuff but not able to deduce how well their pre-clinical and clinical results are correlated. As I understand it, Storm appear to be taking the polar opposite approach to RAC by inhibiting METTL3 and trying to reduce m6A levels, in contrast with RAC trying to inhibit FTO and increase m6A levels.
RAC: more m6A = good.
Storm: less m6A = good.
Who will be right in the end? Maybe it depends...
Definitely a project for someone with the capabilities of @Mason14, not me.
LOL. Unfortunately you are seriously overestimating my molecular...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.76 |
Change
0.050(2.92%) |
Mkt cap ! $311.6M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.96 | $1.76 | $642.2K | 344.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 470 | $1.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.78 | 3359 | 2 |
View Market Depth
| Last trade - 12.30pm 26/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |